English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Diffuse large B-cell lymphoma (DLBCL) is the commonest type of non-Hodgkin lymphoma (NHL) and accounts for 30–40% of all NHL cases worldwide (1). Owing to its heterogeneity, the prognosis of DLBCL varies. After undergoing standard initial treatment (such as the R-CHOP-21 regimen), 40–50% of patients with DLBCL experience refractory disease or relapse (2,3). Therefore, the outcome of DLBCL should be predicted at the time of diagnosis to guide the intensity of subsequent treatment among patients with DLBCL. The International Prognostic Index (IPI) consisting of age, Ann Arbor staging, serum lactate dehydrogenase (LDH) level, performance status, and the number of Original Article

High pretreatment plasma D-dimer levels predict poor survival in patients with diffuse large B-cell lymphoma in the real world